The application of nanoparticle-mediated siRNA delivery systems in ovarian cancer

IF 6.4 3区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Cancer gene therapy Pub Date : 2026-03-27 DOI:10.1038/s41417-026-01020-z

Xueqian Qian, Yi Yuan, Yaning Zhang, Zemin Dou, Chengjin Gao, Yangyang Han

{"title":"The application of nanoparticle-mediated siRNA delivery systems in ovarian cancer","authors":"Xueqian Qian, Yi Yuan, Yaning Zhang, Zemin Dou, Chengjin Gao, Yangyang Han","doi":"10.1038/s41417-026-01020-z","DOIUrl":null,"url":null,"abstract":"Ovarian cancer is one of the most common gynecological malignancies and has the highest mortality rate among gynecological cancers. Its difficulties in diagnosis, high mortality rate, high recurrence rate, and poor prognosis, have always been a major obstacle for researchers. Gene therapy, a revolutionary medical approach, can correct genetic defects to treat intractable diseases, enable personalized medicine, and boost medical research, thus holding great promise for reshaping healthcare. siRNA interference technology has become one of the key directions in drug research field due to its advantages of high efficiency, high specificity, and low toxicity. And the development of new targeted drugs using siRNA interference technology has attracted significant attention. However, siRNA needs to overcome the vascular barrier, achieve intracellular uptake and escape from lysosomes, while also avoiding degradation by nucleases. Fortunately, the emergence of nanomaterials has provided new insights and strategies for siRNA drug delivery. Herein, we review the current advances in nanoparticle-mediated siRNA delivery strategies, as well as the application of siRNA-loaded nanomaterials in the diagnosis and therapy of ovarian cancer.","PeriodicalId":9577,"journal":{"name":"Cancer gene therapy","volume":"33 5","pages":"624-641"},"PeriodicalIF":6.4000,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer gene therapy","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41417-026-01020-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Ovarian cancer is one of the most common gynecological malignancies and has the highest mortality rate among gynecological cancers. Its difficulties in diagnosis, high mortality rate, high recurrence rate, and poor prognosis, have always been a major obstacle for researchers. Gene therapy, a revolutionary medical approach, can correct genetic defects to treat intractable diseases, enable personalized medicine, and boost medical research, thus holding great promise for reshaping healthcare. siRNA interference technology has become one of the key directions in drug research field due to its advantages of high efficiency, high specificity, and low toxicity. And the development of new targeted drugs using siRNA interference technology has attracted significant attention. However, siRNA needs to overcome the vascular barrier, achieve intracellular uptake and escape from lysosomes, while also avoiding degradation by nucleases. Fortunately, the emergence of nanomaterials has provided new insights and strategies for siRNA drug delivery. Herein, we review the current advances in nanoparticle-mediated siRNA delivery strategies, as well as the application of siRNA-loaded nanomaterials in the diagnosis and therapy of ovarian cancer.

Abstract Image

查看原文本刊更多论文

纳米颗粒介导的siRNA递送系统在卵巢癌中的应用。

卵巢癌是最常见的妇科恶性肿瘤之一，在妇科癌症中死亡率最高。该病诊断困难、死亡率高、复发率高、预后差，一直是困扰研究人员的一大难题。基因治疗是一种革命性的医学方法，可以纠正基因缺陷，治疗顽固性疾病，实现个性化医疗，促进医学研究，从而重塑医疗保健的巨大希望。siRNA干扰技术以其高效、高特异性、低毒性等优点，已成为药物研究领域的重点方向之一。而利用siRNA干扰技术开发新的靶向药物引起了人们的极大关注。然而，siRNA需要克服血管屏障，实现细胞内摄取并从溶酶体中逃逸，同时还要避免被核酸酶降解。幸运的是，纳米材料的出现为siRNA给药提供了新的见解和策略。在此，我们综述了纳米颗粒介导的siRNA递送策略的最新进展，以及siRNA负载纳米材料在卵巢癌诊断和治疗中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer gene therapy 医学-生物工程与应用微生物

CiteScore

10.20

自引率

0.00%

发文量

150

审稿时长

4-8 weeks

期刊介绍： Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair. Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.